Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MALT Lymphomas.

Sami N Malek1, Amy J Hatfield, Ian W Flinn

  • 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB Room 388, Baltimore, MD 21231, USA.

Current Treatment Options in Oncology
|August 29, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.

HemaSphere·2026
Same author

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Journal of hematology & oncology·2026
Same author

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Blood·2026
Same author

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

medRxiv : the preprint server for health sciences·2026
Same author

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Blood·2026
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Mucosa-associated lymphoid tissue (MALT) lymphomas are indolent tumors often localized to various organs. Treatment for these MALT lymphomas is tailored to the specific organ and stage, with Helicobacter pylori eradication being key for gastric MALT lymphomas.

Area of Science:

  • Oncology
  • Hematology
  • Pathology

Background:

  • Mucosa-associated lymphoid tissue (MALT) lymphomas are a group of indolent neoplasms.
  • These lymphomas can arise in various extranodal sites, including the orbit, conjunctiva, salivary glands, skin, thyroid, lungs, stomach, and intestine.
  • They are typically characterized by localized disease and a slow clinical progression.

Purpose of the Study:

  • To provide a comprehensive overview of the diagnosis, staging, and treatment strategies for MALT lymphomas.
  • To highlight the organ-specific management approaches for MALT lymphomas.
  • To discuss the evolving role of surgery and the standard of care for different stages and subtypes of MALT lymphomas.

Main Methods:

  • Diagnosis relies on pathologic evaluation of tissue biopsies.

Related Experiment Videos

  • Staging involves a thorough history and physical examination, laboratory tests, imaging (CT scans), bone marrow biopsy, and specialized consultations (ENT, endoscopy).
  • Tumor analysis includes cytogenetic and immunohistochemical assessments.

    • Main Results:

    • Helicobacter pylori eradication is the standard treatment for H. pylori-positive gastric MALT lymphomas, achieving high response rates (60-90%) for early-stage disease.
    • Localized MALT lymphomas in organs like the orbit, conjunctiva, salivary glands, and thyroid are successfully treated with radiotherapy.
    • Advanced or refractory disease may require radiotherapy, surgery, or chemotherapy (e.g., CHOP regimen for high-grade components).

    Conclusions:

    • Treatment for MALT lymphomas must be individualized based on organ involvement, disease stage, and tumor characteristics.
    • While H. pylori eradication is highly effective for gastric MALT lymphomas, other therapeutic modalities like radiotherapy, surgery, and chemotherapy remain crucial for specific presentations.
    • Disseminated MALT lymphomas are generally incurable and managed palliatively with chemotherapy.